Histone deacetylase function in CD4+ T cells
W Ellmeier, C Seiser - Nature Reviews Immunology, 2018 - nature.com
Nature Reviews Immunology, 2018•nature.com
The differentiation of T helper cell subsets and their acquisition of effector functions are
accompanied by changes in gene expression programmes, which in part are regulated and
maintained by epigenetic processes. Histone deacetylases (HDACs) and histone
acetyltransferases (HATs) are key epigenetic regulators that function by mediating dynamic
changes in the acetylation of histones at lysine residues. In addition, many non-histone
proteins are also acetylated, and reversible acetylation affects their functional properties …
accompanied by changes in gene expression programmes, which in part are regulated and
maintained by epigenetic processes. Histone deacetylases (HDACs) and histone
acetyltransferases (HATs) are key epigenetic regulators that function by mediating dynamic
changes in the acetylation of histones at lysine residues. In addition, many non-histone
proteins are also acetylated, and reversible acetylation affects their functional properties …
Abstract
The differentiation of T helper cell subsets and their acquisition of effector functions are accompanied by changes in gene expression programmes, which in part are regulated and maintained by epigenetic processes. Histone deacetylases (HDACs) and histone acetyltransferases (HATs) are key epigenetic regulators that function by mediating dynamic changes in the acetylation of histones at lysine residues. In addition, many non-histone proteins are also acetylated, and reversible acetylation affects their functional properties, demonstrating that HDACs mediate effects beyond the epigenetic regulation of gene expression. In this Review, we discuss studies revealing that HDACs are key regulators of CD4+ T cell-mediated immunity in mice and humans and that HDACs are promising targets in T cell-mediated immune diseases. Finally, we discuss unanswered questions and future research directions to promote the concept that isoform-selective HDAC inhibitors might broaden the clinical application of HDAC inhibitors beyond their current use in certain types of cancer.
nature.com